论文部分内容阅读
目的:探讨210例儿童急性上呼吸道感染发热的临床用药情况。方法:将2015年1月1日~2016年12月31日期间我院收治的210例急性上呼吸道感染发热患儿分为三组,A组应用孟鲁司特钠治疗;B组应用抗生素治疗;C组联合应用孟鲁司特钠与抗生素治疗,比较三组患儿的咳嗽症状积分。结果:三组治疗前咳嗽症状积分差异不明显(P>0.05);治疗后,A组与C组患儿的咳嗽症状积分均比治疗前有明显降低(P<0.05),唯有B组患儿治疗后的咳嗽症状积分与治疗前比较无显著差异(P>0.05)。结论:若使用抗生素治疗后无法明显缓解急性上呼吸道感染发热患儿的临床症状,则可考虑加用白三烯受体拮抗剂孟鲁司特钠,且联合用药的安全性能够保证,无严重不良反应,可在临床推广。
Objective: To investigate the clinical medication of 210 cases of acute upper respiratory tract infection in children. Methods: A total of 210 children with acute upper respiratory tract infection who were admitted to our hospital from January 1, 2015 to December 31, 2016 were divided into three groups: group A was treated with montelukast sodium; group B was treated with antibiotics ; C group were treated with montelukast sodium and antibiotics, cough symptom scores in three groups were compared. Results: There was no significant difference in cough symptom scores between the three groups before treatment (P> 0.05). After treatment, the cough symptom scores in both groups A and C were significantly lower than those before treatment (P <0.05) Children treated cough symptom score and no significant difference (P> 0.05). Conclusion: If the use of antibiotics can not significantly relieve the clinical symptoms of children with fever caused by acute upper respiratory tract infection, we may consider adding montelukast sodium antagonist of leukotriene receptor, and the safety of combination therapy can be guaranteed without serious Adverse reactions, can be clinically promoted.